Advertisement
Supplier News
Subscribe to Supplier News

The Lead

Former Sanofi CEO Joins Puretech’s Board of Directors

February 27, 2015 1:29 pm | News | Comments

PureTech, a science and technology R&D company focused  on identifying, inventing and commercializing disruptive products and technologies in the healthcare sector, announced today the appointment of Christopher Viehbacher, former CEO and Member of the Board of Directors of Sanofi, to its Board of Directors.  Read more...

NY Attorney General Expands Herbal Supplement Investigation

February 24, 2015 9:00 am | by Mary Esch, Associated Press | News | Comments

New York's attorney general is targeting manufacturers of the popular products. Read more...

Cryoport, Sanaria Expand Logistics Partnership Supporting Malaria Vaccines

February 24, 2015 8:55 am | News | Comments

This collaboration includes continued support of Sanaria’s production of malaria vaccine as well...

Senior Pharmaceutical Executives Establish Business, next20

February 18, 2015 10:03 am | News | Comments

Three highly-experienced pharmaceutical and healthcare industry executives have formed next20, a...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

FDA Approves New Dosage for Noven's Osteoporosis Drug

February 13, 2015 11:05 am | News | Comments

The new dosage is now available by prescription nationwide. Read more...                               

BioMed Realty Breaks Ground on Life Science Development

February 12, 2015 2:55 pm | News | Comments

​Joined by San Diego political leaders and representatives of the life science community, BioMed Realty Trust, Inc. broke ground on a new 316,000 square foot laboratory and office campus designed to meet the unique real estate needs of San Diego's thriving life science industry. Read more...

Achillion Shares Soar Following Hepatitis C Drug Update

February 9, 2015 11:57 am | by Associated Press | News | Comments

Shares of Achillion Pharmaceuticals Inc. jumped Monday morning after the drug developer said a small group of patients who took its experimental hepatitis C treatment combination remained free of the liver-destroying virus three months after they stopped taking doses. Read more...

Advertisement

Meet the New ACS CEO: Tom Connelly

February 6, 2015 4:33 pm | by Michelle Taylor, Editor-in-Chief, Laboratory Equipment | Articles | Comments

Come February 17, Thomas M. Connelly, Jr. will be the new CEO of the American Chemical Society (ACS), taking over for Madeleine Jacobs, who is retiring after 11 years as CEO and a total of 24 years with ACS. Connelly talks about the challenges the chemistry industry faces today. Read more... 

GSK Expands Portfolio of Asthma/COPD Medicines in U.S.

January 26, 2015 10:55 am | by GSK | News | Comments

GlaxoSmithKline plc announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the U.S. Read more...                             

FDA Recommends Approval of Astellas' Fungal Infection Treatment

January 23, 2015 1:18 pm | News | Comments

The Advisory Committee's recommendation is based on data from the cresemba development program. Read more...                          

Innovent Biologics Completes $100 Million Series C Financing

January 23, 2015 8:54 am | by Innovent Biologics | News | Comments

Innovent Biologics, Inc., a privately held Chinese biopharmaceutical company dedicated to the development and manufacturing of complex, high-end biologics to be marketed in the rapidly growing Chinese market and elsewhere worldwide that meet EMEA and FDA/cGMP standards, has raised$100 million in Series C financing. Legend Capital led the financing. Read more...

Colorectal Cancer Treatment Market Value to Hit $9.4B by 2020

January 22, 2015 12:01 pm | by GBI Research | News | Comments

The value of the Colorectal Cancer (CRC) therapeutics market will increase moderately, from $8.3 billion in 2013 to $9.4 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 1.8%, according to business intelligence provider GBI Research.

Advertisement

Boehringer Ingelheim: Inhalation Spray Available in U.S.

January 21, 2015 9:53 am | by Boehringer Ingelheim | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. announced that Spiriva Respimat(tiotropium bromide) Inhalation Spray is now available by prescription through retail pharmacies across the United States. Read more...                                                         

Article Galaxy Widget: Time-Saving Research Tool

January 20, 2015 12:17 pm | by DeepDyrve | News | Comments

Reprints Desk, Inc., a Research Solutions company and top-rated document delivery supplier, has officially launched its Article Galaxy Widget, a time-saving tool that provides web browser access to scientific, technology and medical (STM) research articles indexed by more than 50 popular search sites and discovery databases, like Google Scholar, PubMed, ResearchGATE, Web of Science and Scopus. Read more...

MRIGlobal Wins $54 Million NIH Neurological Disorders And Stroke Contract

January 16, 2015 11:25 am | News | Comments

MRIGlobal announced that it has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials. Read more...

UroSens Gets $2M to Commercialize Bladder, Prostate Cancer Test

January 12, 2015 11:21 am | by UroSens | News | Comments

UroSens Ltd, a diagnostic company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has announced it has received £2 million ($3.02 million) investment. Read more...                                            

Clementia Pharmaceuticals: New Site for FOP Trial

January 12, 2015 11:15 am | News | Comments

Clementia Pharmaceuticals, Inc. announced the opening of a new site in Paris, France for the Phase 2 clinical trial of palovarotene, the company's lead product candidate for the treatment of fibrodysplasia ossificans progressiva (FOP).  Read more...      

Advertisement

FDA Endorses First Low Cost Biotech Drug

January 8, 2015 8:26 am | by Matthew Perrone - AP Health Writer | News | Comments

Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. Read more...              

ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial

January 7, 2015 10:51 am | News | Comments

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100.  

Market for Testing On Tissues, Cells Reaches $7.5B

December 19, 2014 1:06 pm | News | Comments

Driven by new technologies and the need to discover biomarkers, the tissue and cell-based diagnostic market grew to an estimated 7.4 billion in revenues in 2013 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories. Read more...

China Pledges to Speed Entry of U.S. Pharmaceuticals

December 19, 2014 8:37 am | by Jason Keyser - Associated Press | News | Comments

China promised Thursday to speed up imports of pharmaceuticals and medical devices from the United States. Read more...                         

New Report: Hep C's Decades of Drug Research Failures, Successes

December 18, 2014 5:18 pm | by PhRMA | News | Comments

PhRMA released a new report, "Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones," that examines the scientific challenges and setbacks researchers have faced on the path to developing new medicines with the potential to transform treatment for hepatitis C patients and how these so-called "failures" are an integral part of the drug discovery process. Read more...

PDI Announces Launch of NGS Test for Cancer Risk Assessment

December 17, 2014 12:07 pm | News | Comments

PDI, Inc. announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Read more...

Pfizer: Breast Cancer Treatment Results

December 16, 2014 9:17 am | News | Comments

Pfizer Inc. announced the publication of the detailed results from PALOMA-1, a randomized Phase 2 study of palbociclib in combination with letrozole versus letrozole alone, in The Lancet Oncology.  Read more...             

Actavis Launches Generic Version of Celebrex

December 11, 2014 9:09 am | News | Comments

Actavis plc announced that it has launched a generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules, as part of a settlement agreement with Pfizer, Inc.  Read more...                                   

Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 12:27 pm | by Tom Murphy - AP Business Writer | News | Comments

Merck will spend $8.4 billion to buy Cubist Pharmaceuticals. Read more...                                

Vaximm Receives Positive Data from Oral Cancer Vaccine Trial

December 4, 2014 9:40 am | News | Comments

Vaximm AG, a Swiss-German biotech company focusing on oral cancer vaccines, announced follow-on data from the first clinical trial of its investigational oral T-cell vaccine VXM01. Data of a trial extension of the randomized, placebo-controlled, double-blind Phase 1 dose escalation study show that the safety profile to date is manageable.  Read More...

FDA Approves Amgen's ALL Treatment

December 3, 2014 5:10 pm | News | Comments

Amgen announced that the U.S. Food and Drug Administration (FDA) has granted approval of Blincyto (blinatumomab) for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read more...

The Cystic Fibrosis Foundation's Controversial New Cash

November 26, 2014 12:00 pm | by Ryan Bushey, Associate Editor | Articles | Comments

Concerns have been raised relating to a lucrative investment the Cystic Fibrosis Foundation made in a biotechnology company. Read more...                    

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading